Core Insights - Ascentage Pharma announced results from 13 studies of its key assets, including olverembatinib and APG-5918, at the 2025 European Hematology Association Annual Congress, highlighting their potential in treating unmet medical needs in cancers [1][2][3] Group 1: Olverembatinib - Olverembatinib, a third-generation tyrosine kinase inhibitor, showed significant clinical benefits in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), with high complete remission (CR) and complete molecular response (CMR) rates [2] - In a study combining olverembatinib with blinatumomab, all patients achieved CR after one treatment cycle, with an overall survival (OS) rate of 100% and an event-free survival (EFS) rate of 91.6% at 18 months [6] - The combination of olverembatinib with the VP regimen resulted in a 100% overall response rate (ORR) and a 97.3% CR rate, indicating its effectiveness as a first-line therapy for adult patients with Ph+ ALL [11] Group 2: APG-5918 - APG-5918, an investigational EED inhibitor, demonstrated potent antitumor activity in preclinical studies for T-cell lymphoma, supporting its further clinical development [3][18] - The combination of APG-5918 with histone deacetylase inhibitor tucidinostat showed enhanced antitumor effects, indicating its potential as a therapeutic option [18] Group 3: Company Overview - Ascentage Pharma is focused on addressing unmet medical needs in cancers and has developed a pipeline of innovative drug candidates, including olverembatinib and APG-5918 [13] - The company is conducting global registrational Phase III trials for olverembatinib in various indications, including newly diagnosed Ph+ ALL and GIST patients [14]
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL